27261587|t|Combination of telmisartan with sildenafil ameliorate progression of diabetic nephropathy in streptozotocin - induced diabetic model
27261587|a|Diabetic nephropathy (DN) is a leading cause of end-stage renal disease in the world. Several signaling pathways are involved in the pathogenesis of DN including elevation in level of angiotensin II, formation of advanced glycation end products (AGE), activation of protein kinase c (PKC), and lipid accumulation. These pathways activate one another mutually leading to oxidative stress, increasing expression of transforming growth factor beta-1 (TGF-β 1) and release of interleukins and adhesion molecules, so the aim of this study is to interrupt more than pathogenic pathway to ameliorate the progression of DN. In the present study, white male rats (N=48) were divided into six groups (8 rats each), the first two groups served as normal control and a control vehicle group while the remaining four groups were rendered diabetic by a single intraperitoneal injection of Streptozotocin (STZ) and being left for 4 weeks to develop DN. Thereafter, the rats were divided into DN group, DN group receiving Telmisartan or Sildenafil or Telmisartan Sildenafil combination. After the specified treatment period, urine samples were collected (using metabolic cages) to measure proteinuria, animals were then euthanized, blood and tissue samples were collected for measurement of Blood glucose, BUN, S.Cr, LDL, NO, TGF-β1, IL-1β, AGEPs, and SOD. The combination therapy showed significant decrease in BUN, S.Cr, LDL, TGF-β1, IL-1β, Proteinuria and AGEPs and significant increase in SOD and NO. The findings showed that combination therapy was able to ameliorate DN and that the effects were superior to the single drugs alone.
27261587	0	11	Combination	T121	C0013162
27261587	15	26	telmisartan	T109,T121	C0248719
27261587	32	42	sildenafil	T109,T121	C0529793
27261587	43	53	ameliorate	T080	C0205556
27261587	54	65	progression	T046	C0242656
27261587	69	89	diabetic nephropathy	T047	C0011881
27261587	93	107	streptozotocin	T109,T195	C0038432
27261587	110	117	induced	T169	C0205263
27261587	118	126	diabetic	T033	C0241863
27261587	133	153	Diabetic nephropathy	T047	C0011881
27261587	155	157	DN	T047	C0011881
27261587	181	204	end-stage renal disease	T047	C0022661
27261587	227	245	signaling pathways	T044	C0037080
27261587	266	278	pathogenesis	T046	C0699748
27261587	282	284	DN	T047	C0011881
27261587	295	304	elevation	T082	C0702240
27261587	317	331	angiotensin II	T116,T121,T123	C0003009
27261587	333	342	formation	T169	C1522492
27261587	346	377	advanced glycation end products	T109,T123	C0162574
27261587	379	382	AGE	T109,T123	C0162574
27261587	385	395	activation	T043	C1819041
27261587	399	415	protein kinase c	T116,T126	C0033634
27261587	417	420	PKC	T116,T126	C0033634
27261587	427	445	lipid accumulation	T033	C0333574
27261587	453	461	pathways	T044	C0037080
27261587	462	470	activate	T052	C1879547
27261587	503	519	oxidative stress	T049	C0242606
27261587	532	542	expression	T045	C1171362
27261587	546	579	transforming growth factor beta-1	T116,T121,T123	C1704256
27261587	581	588	TGF-β 1	T116,T121,T123	C1704256
27261587	594	601	release	T169	C1283071
27261587	605	617	interleukins	T116,T129	C0021764
27261587	622	640	adhesion molecules	T116,T123	C0007578
27261587	693	703	pathogenic	T033	C3816499
27261587	704	711	pathway	T077	C1705987
27261587	715	725	ameliorate	T080	C0205556
27261587	730	741	progression	T046	C0242656
27261587	745	747	DN	T047	C0011881
27261587	764	769	study	T062	C0008972
27261587	771	786	white male rats	T015	C0684072
27261587	826	830	rats	T015	C0684072
27261587	869	883	normal control	T096	C0009932
27261587	890	911	control vehicle group	T096	C0009932
27261587	958	966	diabetic	T033	C0241863
27261587	979	1004	intraperitoneal injection	T061	C0021493
27261587	1008	1022	Streptozotocin	T109,T195	C0038432
27261587	1024	1027	STZ	T109,T195	C0038432
27261587	1067	1069	DN	T047	C0011881
27261587	1087	1091	rats	T015	C0684072
27261587	1110	1112	DN	T047	C0011881
27261587	1120	1122	DN	T047	C0011881
27261587	1139	1150	Telmisartan	T109,T121	C0248719
27261587	1154	1164	Sildenafil	T109,T121	C0529793
27261587	1168	1179	Telmisartan	T109,T121	C0248719
27261587	1180	1190	Sildenafil	T109,T121	C0529793
27261587	1191	1202	combination	T121	C0013162
27261587	1214	1223	specified	T080	C0205369
27261587	1224	1233	treatment	T169	C0039798
27261587	1234	1240	period	T079	C1948053
27261587	1242	1255	urine samples	T031	C1610733
27261587	1261	1270	collected	T078	C1516695
27261587	1278	1293	metabolic cages	T073	C3273359
27261587	1306	1317	proteinuria	T033	C0033687
27261587	1319	1326	animals	T008	C0003062
27261587	1337	1347	euthanized	T054	C0162665
27261587	1349	1354	blood	T031	C0178913
27261587	1359	1373	tissue samples	T024	C1292533
27261587	1379	1388	collected	T078	C1516695
27261587	1393	1421	measurement of Blood glucose	T059	C0392201
27261587	1423	1426	BUN	T059	C0005845
27261587	1428	1432	S.Cr	T059	C0201976
27261587	1434	1437	LDL	T059	C0202117
27261587	1439	1441	NO	T059	C3810607
27261587	1443	1449	TGF-β1	T059	C3889969
27261587	1451	1456	IL-1β	T059	C3815172
27261587	1458	1463	AGEPs	T059	C0022885
27261587	1469	1472	SOD	T059	C0022885
27261587	1478	1497	combination therapy	T061	C0013218
27261587	1529	1532	BUN	T123,T197	C0600137
27261587	1534	1538	S.Cr	T109,T123	C0010294
27261587	1540	1543	LDL	T109,T123	C0023823
27261587	1545	1551	TGF-β1	T116,T121,T123	C1704256
27261587	1553	1558	IL-1β	T116,T129	C0021753
27261587	1560	1571	Proteinuria	T033	C0033687
27261587	1576	1581	AGEPs	T109,T123	C0162574
27261587	1610	1613	SOD	T116,T121,T126	C0038838
27261587	1618	1620	NO	T121,T123,T197	C0028128
27261587	1647	1666	combination therapy	T061	C0013218
27261587	1679	1689	ameliorate	T080	C0205556
27261587	1690	1692	DN	T047	C0011881
27261587	1719	1727	superior	T080	C0205556
27261587	1742	1747	drugs	T121	C0013227